Skip to main content

Health condition · Clinically reviewed

Gaucher disease, enzyme replacement, oral options and specialist UK care.

The most common lysosomal storage disorder. With targeted enzyme replacement, oral substrate reduction therapy and coordinated NHS specialist care, most people with Type 1 disease live full lives.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NHS specialised commissioning, EWGGD and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including enzyme replacement therapy, substrate reduction therapy and NHS specialist metabolic centre pathways.

Key facts

Gaucher disease at a glance.

The essentials, in plain English. What it is, the three types, and how it is treated in the UK today.

  • What it is

    The most common lysosomal storage disorder. An autosomal recessive condition where mutations in the GBA1 gene reduce β-glucocerebrosidase enzyme activity, so glucocerebroside builds up in macrophages.

  • Who it affects

    Estimated 1 in 40,000 to 60,000 in the UK general population, with a higher rate in the Ashkenazi Jewish population where carrier frequency is roughly 1 in 15.

  • Three types

    Type 1 (non-neuronopathic) is by far the most common at around 95 percent. Type 2 is acute infantile neuronopathic and severe. Type 3 is chronic neuronopathic with variable neurology.

  • Classic Type 1

    Hepatosplenomegaly, low blood counts, bone pain and pathological fractures, avascular necrosis and delayed growth in children.

  • Foundation therapy

    Enzyme replacement therapy given as an intravenous infusion every two weeks is the mainstay for Type 1 disease under NHS specialised commissioning.

  • Linked conditions

    GBA1 carriers and patients have a five to ten times higher risk of Parkinson’s disease, and a raised risk of monoclonal gammopathies, multiple myeloma and pulmonary hypertension.

Why this guide matters

A treatable rare disease, when caught in time.

Gaucher disease is rare, but a simple blood test can confirm it and treatment changes the trajectory. These three points shape everything else on this page.

  • A blood spot confirms the diagnosis

    A dried blood spot or leucocyte β-glucocerebrosidase assay is the definitive test. Bone marrow biopsy is not needed.

  • ERT is the mainstay for Type 1

    Fortnightly intravenous enzyme replacement therapy reduces spleen and liver size, corrects blood counts and settles bone disease.

  • Care is centralised in the NHS

    Specialised commissioning routes all UK patients to a small number of expert metabolic centres for lifelong follow-up.

How the diagnosis is made

From suspicion to a confirmed diagnosis.

The steps a UK GP, haematologist or metabolic specialist will normally follow, in order. So you know what to expect and why.

  1. 01

    Suspecting

    Clinical suspicion

    Unexplained splenomegaly, low platelets, bone pain, easy bruising or a positive Ashkenazi Jewish family history should trigger targeted testing.

  2. 02

    Suspecting

    Full blood count and film

    Anaemia and thrombocytopenia are common. A bone marrow biopsy may show Gaucher cells but is not needed to confirm the diagnosis.

  3. 03

    Suspecting

    Enzyme assay

    A blood spot or leucocyte β-glucocerebrosidase assay is the definitive first-line test. Low enzyme activity confirms the diagnosis.

  4. 04

    Confirming

    GBA1 genetic testing

    Molecular testing of the GBA1 gene confirms the pathogenic variants and supports family testing and carrier counselling.

  5. 05

    Confirming

    Baseline biomarkers

    Chitotriosidase, glucosylsphingosine and ferritin are used to monitor disease activity over time in specialist centres.

  6. 06

    Referring

    MRI bone marrow burden score

    Whole-body or femoral MRI grades marrow infiltration and picks up early avascular necrosis before pain sets in.

  7. 07

    Referring

    Specialist referral

    All confirmed cases are referred to an NHS specialised commissioning metabolic centre such as the Royal Free London, Salford, or Great Ormond Street for children.

Typical timeline: from first blood test to specialist plan in weeks, not months.

Symptoms

What Gaucher disease looks like.

The classic mix of hepatosplenomegaly, cytopenias and bone disease. And the features that mean a specialist opinion is needed sooner rather than later.

  • Hepatosplenomegaly

    An enlarged liver and, more prominently, an enlarged spleen are the classic early signs. See our guides on the enlarged spleen and enlarged liver.

  • Low blood counts

    Anaemia, thrombocytopenia and easy bruising are driven by bone marrow infiltration and hypersplenism.

  • Bone pain and bone crises

    Deep, boring bone pain and sudden bone crises are common in the femur and pelvis. Attacks can be mistaken for infection.

  • Avascular necrosis and fractures

    AVN of the hip or knee and pathological fractures reflect long-standing marrow disease and are a strong reason to start treatment early.

  • Delayed growth in children

    Children can present with short stature, delayed puberty and easy fatigue, often before the diagnosis is suspected.

  • Chronic fatigue

    Adults commonly describe a heavy, disabling fatigue that improves with enzyme replacement therapy over months.

  • Neurological features (Types 2 and 3)

    Oculomotor apraxia, seizures, developmental regression or myoclonus point towards a neuronopathic subtype and urgent paediatric metabolic referral.

  • Red flag - unexplained cytopenia

    Splenomegaly with low platelets and no obvious cause should prompt a β-glucocerebrosidase enzyme assay before invasive investigations.

Treatment

How Gaucher disease is treated in the UK.

Enzyme replacement therapy first, oral substrate reduction therapy for eligible adults, and coordinated bone, haematology and genetic care around them.

  • Enzyme replacement therapy (ERT)

    Imiglucerase (Cerezyme), velaglucerase (VPRIV) or taliglucerase (Elelyso) given as an intravenous infusion every two weeks. Lifelong, under NHS specialised commissioning.

  • Substrate reduction therapy (SRT)

    Oral eliglustat (Cerdelga) is offered to eligible adults with Type 1 disease after CYP2D6 genotyping. Miglustat is used selectively where ERT and eliglustat are not suitable.

  • Bone health

    Bisphosphonates, calcium and vitamin D optimisation, plus orthopaedic input for bone pain, fractures and AVN. Total hip replacement is common for advanced AVN.

  • Selective splenectomy

    Rarely needed since ERT became available. Weighed carefully because it can increase the long-term risk of Parkinson’s disease and myeloma.

  • Pain and analgesia

    Bone crises need multimodal analgesia and specialist input rather than antibiotics. Neuropathic agents help chronic bone pain in some patients.

  • Transfusion support

    Selective red cell or platelet transfusions before surgery or during severe crises, until ERT restores marrow function.

  • Specialist genetics

    Genetic counselling for parents and siblings, cascade testing, and preimplantation genetic diagnosis (PGD) or prenatal testing for planned pregnancies.

  • Multidisciplinary follow-up

    Coordinated care across metabolic medicine, haematology, orthopaedics and the Gauchers Association for peer support and advocacy.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, international expert group consensus and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your metabolic specialist knows your history and can tell you which parts apply to you. If in doubt, get seen.

  • NHS England. Specialised services for lysosomal storage disorders (adults and children).

  • European Working Group on Gaucher Disease (EWGGD). Consensus recommendations.

  • International Collaborative Gaucher Group (ICGG). Registry-based management guidance.

  • NICE. Highly specialised technology appraisals for eliglustat and velaglucerase alfa.

  • MHRA. Product information for imiglucerase, velaglucerase alfa, taliglucerase alfa, eliglustat and miglustat.

Red flags

When Gaucher disease needs urgent attention.

Most of the time, Gaucher disease is quietly managed by a specialist team. These are the situations that need faster action.

  • Neurological features in a child

    Oculomotor apraxia, seizures, hypertonia or developmental regression suggest Type 2 or Type 3 disease and need urgent paediatric metabolic review.

  • Acute bone crisis

    Sudden severe bone pain with fever can mimic osteomyelitis. It needs same-day specialist assessment rather than empirical antibiotics.

  • Avascular necrosis

    Deep hip or shoulder pain that persists at night is often AVN. Early MRI protects the joint and guides orthopaedic planning.

  • Severe thrombocytopenia

    Platelets below 50 with bleeding or planned surgery need specialist haematology input and possible transfusion cover.

  • Pulmonary hypertension

    Breathlessness on exertion in a patient with Gaucher disease should prompt echocardiography and specialist pulmonary review.

  • Suspected multiple myeloma

    New back pain, hypercalcaemia or a rising paraprotein deserves urgent haematology assessment given the raised background risk.

  • Parkinsonian features

    Tremor, bradykinesia or REM sleep behaviour disorder should trigger neurology referral and honest counselling about the GBA1-Parkinson’s link.

  • Pregnancy planning

    Family planning conversations should happen early. Prenatal diagnosis and PGD are available through specialist genetics.

  • Missed infusions

    Interruptions in enzyme replacement therapy can worsen cytopenias and bone disease. Continuity of the infusion schedule matters.

Living with it

A rare disease, with a clear plan.

Four things that make the biggest difference day to day. A steady infusion rhythm, gentle attention to your bones, honest family conversations and knowing your own warning signs.

A quiet reminder

Consistency of care changes the long-term picture.

Regular follow-up at a specialist metabolic centre, and steady adherence to therapy, protect bones, blood counts and quality of life over decades.

  1. 01 Routine

    Infusion rhythm

    Fortnightly infusions become part of life. Home infusion is available for stable patients and can transform routine, work and travel.

  2. 02 Movement

    Protect the bones

    Low-impact exercise, weight management and vitamin D keep bones stronger. Contact sports need a conversation with your specialist.

  3. 03 Family

    Talk about genetics

    Siblings and children can be offered testing. Genetic counselling helps every family member decide what is right for them.

  4. 04 Escalate

    Know your warning signs

    New bone pain, breathlessness, bleeding or neurological symptoms deserve early contact with your metabolic centre rather than watchful waiting.

Frequently asked

Everything we get asked about Gaucher disease.

Quick answers on diagnosis, enzyme replacement therapy, oral options and the link with Parkinson’s disease.

  • What is Gaucher disease?

    Gaucher disease is the most common lysosomal storage disorder. It is an autosomal recessive condition caused by mutations in the GBA1 gene, which reduce β-glucocerebrosidase enzyme activity. Glucocerebroside then accumulates in macrophages across the liver, spleen, bone marrow and, in some subtypes, the nervous system.

  • What are the three types of Gaucher disease?

    Type 1 is non-neuronopathic and accounts for about 95 percent of cases. It causes hepatosplenomegaly, cytopenias and bone disease without central nervous system involvement. Type 2 is acute neuronopathic, presents in infancy and is severe and usually fatal. Type 3 is chronic neuronopathic with variable, slowly progressive neurological features.

  • How is Gaucher disease diagnosed?

    The definitive test is a β-glucocerebrosidase enzyme assay, done on a dried blood spot or on leucocytes. GBA1 genetic testing then confirms the pathogenic variants and guides family testing. Imaging with MRI grades the bone marrow burden and picks up avascular necrosis.

  • What is enzyme replacement therapy?

    Enzyme replacement therapy (ERT) uses a recombinant version of the missing enzyme, given as an intravenous infusion every two weeks. Imiglucerase, velaglucerase alfa and taliglucerase alfa are the options used in the UK. ERT reduces spleen and liver size, improves blood counts and settles bone disease over months.

  • Is there a tablet option?

    Yes. Eliglustat (Cerdelga) is an oral substrate reduction therapy licensed for eligible adults with Type 1 disease after CYP2D6 genotyping. Miglustat is used selectively when ERT and eliglustat are not appropriate.

  • Does Gaucher disease increase the risk of Parkinson’s?

    GBA1 carriers and patients have a five to ten times higher risk of Parkinson’s disease compared with the general population. The absolute risk remains modest and most people never develop it, but neurological symptoms should always be discussed with your specialist.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.